What is a stock summary page? Click here for an overview.
Business Description
Chong Kun Dang Pharmaceutical Corp
ISIN : KR7185750007
Compare
Compare
Traded in other countries / regions
185750.Korea Index Membership
KOSPI IPO Date
2013-12-06Description
Chong Kun Dang Pharmaceutical Corp. is a manufacturer of antibiotics. The company manufactures and distributes over 130 ethical, OTC pharmaceuticals and pharmaceutical active ingredients, primarily focusing on the application of its advanced technologies in fermentation and organic synthesis. The product range includes Rifampicin (antituberculosis), DMCT (raw material for Minocycline), Cephalosporins, 7-ACA and other intermediates of Cephalosporins, Cyclosporin A (immunosuppressant) and Lovastatin (antihyperlipidaemic agent).
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.61 | |||||
| Equity-to-Asset | 0.61 | |||||
| Debt-to-Equity | 0.21 | |||||
| Debt-to-EBITDA | 1.41 | |||||
| Interest Coverage | 11.96 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 3.57 | |||||
| Beneish M-Score | -2.16 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 6.9 | |||||
| 3-Year EBITDA Growth Rate | 11.5 | |||||
| 3-Year EPS without NRI Growth Rate | 38.8 | |||||
| 3-Year FCF Growth Rate | 63.6 | |||||
| 3-Year Book Growth Rate | 15.9 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 6.51 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.43 | |||||
| 9-Day RSI | 55.31 | |||||
| 14-Day RSI | 51.87 | |||||
| 3-1 Month Momentum % | -5.38 | |||||
| 6-1 Month Momentum % | -18.56 | |||||
| 12-1 Month Momentum % | -15.56 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.61 | |||||
| Quick Ratio | 1.65 | |||||
| Cash Ratio | 0.82 | |||||
| Days Inventory | 109.03 | |||||
| Days Sales Outstanding | 60.51 | |||||
| Days Payable | 69 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 1.4 | |||||
| Dividend Payout Ratio | 0.13 | |||||
| 3-Year Dividend Growth Rate | 8.4 | |||||
| Forward Dividend Yield % | 1.4 | |||||
| 5-Year Yield-on-Cost % | 2.28 | |||||
| 3-Year Average Share Buyback Ratio | -0.5 | |||||
| Shareholder Yield % | 5.02 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 33.57 | |||||
| Operating Margin % | 6.27 | |||||
| Net Margin % | 6.88 | |||||
| FCF Margin % | -0.11 | |||||
| ROE % | 12.68 | |||||
| ROA % | 7.57 | |||||
| ROIC % | 13.17 | |||||
| 3-Year ROIIC % | 26.81 | |||||
| ROC (Joel Greenblatt) % | 18.73 | |||||
| ROCE % | 11.18 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 9.58 | |||||
| Forward PE Ratio | 12.54 | |||||
| PE Ratio without NRI | 9.31 | |||||
| Shiller PE Ratio | 14.13 | |||||
| Price-to-Owner-Earnings | 10930.33 | |||||
| PEG Ratio | 0.71 | |||||
| PS Ratio | 0.66 | |||||
| PB Ratio | 1.16 | |||||
| Price-to-Tangible-Book | 1.27 | |||||
| Price-to-Operating-Cash-Flow | 16.25 | |||||
| EV-to-EBIT | 8.4 | |||||
| EV-to-EBITDA | 6.92 | |||||
| EV-to-Revenue | 0.58 | |||||
| EV-to-FCF | -509.6 | |||||
| Price-to-GF-Value | 0.83 | |||||
| Price-to-Projected-FCF | 0.73 | |||||
| Price-to-DCF (Earnings Based) | 0.25 | |||||
| Price-to-Median-PS-Value | 0.6 | |||||
| Price-to-Peter-Lynch-Fair-Value | 0.68 | |||||
| Price-to-Graham-Number | 0.73 | |||||
| Price-to-Net-Current-Asset-Value | 2.62 | |||||
| Earnings Yield (Greenblatt) % | 11.9 | |||||
| FCF Yield % | -0.18 | |||||
| Forward Rate of Return (Yacktman) % | 18.56 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Chong Kun Dang Pharmaceutical Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil â‚©) | 1,586,430.796 | ||
| EPS (TTM) (â‚©) | 8220.667 | ||
| Beta | 0.54 | ||
| 3-Year Sharpe Ratio | -0.07 | ||
| 3-Year Sortino Ratio | -0.12 | ||
| Volatility % | 26.34 | ||
| 14-Day RSI | 51.87 | ||
| 14-Day ATR (â‚©) | 1776.018016 | ||
| 20-Day SMA (â‚©) | 77200 | ||
| 12-1 Month Momentum % | -15.56 | ||
| 52-Week Range (â‚©) | 70900 - 124000 | ||
| Shares Outstanding (Mil) | 13.18 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Chong Kun Dang Pharmaceutical Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Chong Kun Dang Pharmaceutical Corp Stock Events
| Event | Date | Price (â‚©) | ||
|---|---|---|---|---|
| No Event Data | ||||
Chong Kun Dang Pharmaceutical Corp Frequently Asked Questions
What is Chong Kun Dang Pharmaceutical Corp(XKRX:185750)'s stock price today?
The current price of XKRX:185750 is â‚©78800.00. The 52 week high of XKRX:185750 is â‚©124000.00 and 52 week low is â‚©70900.00.
When is next earnings date of Chong Kun Dang Pharmaceutical Corp(XKRX:185750)?
The next earnings date of Chong Kun Dang Pharmaceutical Corp(XKRX:185750) is .
Does Chong Kun Dang Pharmaceutical Corp(XKRX:185750) pay dividends? If so, how much?
The Dividend Yield %  of Chong Kun Dang Pharmaceutical Corp(XKRX:185750) is 1.4% (As of Today), Highest Dividend Payout Ratio of Chong Kun Dang Pharmaceutical Corp(XKRX:185750) was 0.27. The lowest was 0.07. And the median was 0.17. The  Forward Dividend Yield % of Chong Kun Dang Pharmaceutical Corp(XKRX:185750) is 1.4%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers